GBDC Stock +24.76% Since The Golden Star Was Identified GBDC Stock +24.76% Since The Golden Star Was Identified Unlock Golden Star List
NASDAQ:ALXN
Delisted

Alexion Pharmaceuticals Stock Price (Quote)

$182.50
+0 (+0%)
At Close: May 27, 2022

Range Low Price High Price Comment
30 days $182.50 $182.50 Friday, 27th May 2022 ALXN stock ended at $182.50. During the day the stock fluctuated 0% from a day low at $182.50 to a day high of $182.50.
90 days $182.50 $182.50
52 weeks $174.72 $187.45

Historical Alexion Pharmaceuticals prices

Date Open High Low Close Volume
2019-02-20 $128.51 $130.42 $128.45 $129.84 1 758 158
2019-02-19 $128.48 $129.78 $128.05 $128.93 1 169 679
2019-02-15 $125.44 $129.49 $125.44 $129.42 1 299 915
2019-02-14 $124.73 $126.23 $123.94 $125.93 1 017 026
2019-02-13 $125.00 $125.30 $123.21 $125.18 1 160 511
2019-02-12 $121.70 $124.37 $121.43 $124.26 1 701 834
2019-02-11 $120.76 $121.40 $119.29 $120.05 969 076
2019-02-08 $118.03 $120.19 $117.80 $120.14 1 057 608
2019-02-07 $119.57 $120.37 $117.31 $118.79 1 479 412
2019-02-06 $122.72 $123.10 $120.94 $121.03 1 556 601
2019-02-05 $123.39 $124.88 $121.56 $122.87 1 889 051
2019-02-04 $128.67 $129.00 $121.43 $123.75 3 629 816
2019-02-01 $124.44 $126.51 $123.15 $126.28 2 470 357
2019-01-31 $121.41 $123.21 $120.44 $122.96 1 678 082
2019-01-30 $119.62 $121.65 $117.66 $121.32 1 427 945
2019-01-29 $119.32 $119.99 $117.12 $119.61 2 276 474
2019-01-28 $119.87 $120.01 $117.00 $119.21 2 012 087
2019-01-25 $118.98 $121.59 $118.37 $121.44 1 501 610
2019-01-24 $117.25 $117.98 $116.38 $117.91 1 557 372
2019-01-23 $115.14 $117.98 $114.83 $117.00 2 480 505
2019-01-22 $115.28 $115.32 $112.14 $114.29 2 841 642
2019-01-18 $115.70 $117.37 $113.54 $117.05 2 528 349
2019-01-17 $111.62 $115.65 $111.10 $114.62 1 926 632
2019-01-16 $111.89 $113.99 $110.81 $111.70 2 158 053
2019-01-15 $108.17 $111.77 $107.76 $111.73 1 949 308
Click to get the best stock tips daily for free!

About Alexion Pharmaceuticals

Alexion Pharmaceuticals Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosp... ALXN Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT